IL287516B1
Therapeutic uses of empagliflozin
Abstract
This record has no abstract on file.
Term
No projected expiry on record.
- Priority
- Filed
- Published
- Today
72 members in 24 offices
Priority claims7
| Document | Office | Kind | Date |
|---|---|---|---|
| 201361808807 | United States of America | P | |
| 2812016 | Canada | A | |
| 201361823041 | United States of America | P | |
| 201361835809 | United States of America | P | |
| 201361835811 | United States of America | P | |
| 201461942301 | United States of America | P | |
| 2014056655 | European Patent Office (EPO) | W |
Members72
| Document | Office | Kind | |
|---|---|---|---|
| CA2812016A1 | Canada | A1 | |
| CA2908621A1 | Canada | A1 | |
| US2014303097A1 | United States of America | A1 | |
| WO2014161918A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2014247091A1 | Australia | A1 | |
| IL241101A0 | Israel | A0 | |
| IL241101D0 | Israel | D0 | |
| KR20150138859A | Republic of Korea | A | |
| US2016000816A1 | United States of America | A1 | |
| CN105263485A | China | A | |
| PH12015502276A1 | Philippines | A1 | |
| PH12015502276B1 | Philippines | B1 | |
| EP2981255A1 | European Patent Office (EPO) | A1 | |
| US2016038523A1 | United States of America | A1 | |
| EA201500996A1 | Eurasian Patent Organization (EAPO) | A1 | |
| JP2016515599A | Japan | A | |
| HK1213818A | Hong Kong, China | A | |
| HK1213818A1 | Hong Kong, China | A1 | |
| MX2015013948A | Mexico | A | |
| CL2015002941A1 | Chile | A1 | |
| US9949997B2 | United States of America | B2 | |
| JP6325084B2 | Japan | B2 | |
| JP2018131448A | Japan | A | |
| AU2014247091B2 | Australia | B2 | |
| US2019015437A1 | United States of America | A1 | |
| US2019038654A1 | United States of America | A1 | |
| CN109512831A | China | A | |
| AU2019202568A1 | Australia | A1 | |
| CN110075301A | China | A | |
| JP6672365B2 | Japan | B2 | |
| EA035181B1 | Eurasian Patent Organization (EAPO) | B1 | |
| JP2020109100A | Japan | A | |
| JP2020109100A | Japan | A | |
| IL276289A | Israel | A | |
| IL276289D0 | Israel | D0 | |
| IL241101A | Israel | A | |
| IL241101B | Israel | B | |
| US2020360412A1 | United States of America | A1 | |
| US2020368261A1 | United States of America | A1 | |
| NZ711659A | New Zealand | A | |
| PH12020500352A1 | Philippines | A1 | |
| AU2019202568B2 | Australia | B2 | |
| KR102318207B1 | Republic of Korea | B1 | |
| KR20210131442A | Republic of Korea | A | |
| US2021346418A1 | United States of America | A1 | |
| IL287516A | Israel | A | |
| IL287516D0 | Israel | D0 | |
| IL276289B | Israel | B | |
| US2022110961A1 | United States of America | A1 | |
| JP2022069476A | Japan | A | |
| CA2908621C | Canada | C | |
| EP2981255B1 | European Patent Office (EPO) | B1 | |
| MX2020013740A | Mexico | A | |
| DK2981255T3 | Denmark | T3 | |
| PT2981255T | Portugal | T | |
| LT2981255T | Lithuania | T | |
| FI2981255T3 | Finland | T3 | |
| ES2930655T3 | Spain | T3 | |
| RS63721B1 | Serbia | B1 | |
| HRP20221368T1 | Croatia | T1 | |
| PL2981255T3 | Poland | T3 | |
| EP4119136A1 | European Patent Office (EPO) | A1 | |
| HUE060721T2 | Hungary | T2 | |
| KR20230074293A | Republic of Korea | A | |
| IL287516B1This record | Israel | B1 | |
| US11813275B2 | United States of America | B2 | |
| US11918596B2 | United States of America | B2 | |
| JP2024059725A | Japan | A | |
| US2024156848A1 | United States of America | A1 | |
| JP7541641B2 | Japan | B2 | |
| MX378422B | Mexico | B | |
| US2025345352A1 | United States of America | A1 |
Numbers
- Publication
- 287516
- Application
- 287516
Titles2
- English
- Therapeutic uses of empagliflozin
- Hebrew
- שימושים רפואיים באמפאגליפלוזין
Classification
- CPC, 19
- A61K31/155
- A61K31/7048
- A61K31/522
- A61P3/00
- A61P3/10
- A61P9/00
- A61P9/10
- A61P9/14
- A61P39/00
- A61P39/06
- A61P43/00
- A61K9/2018
- A61K9/2866
- A61K31/7034
- A61K45/06
- A61P9/04
- A61K2300/00
- A61K9/0053
- A61P1/18
- IPC, 8
- A61K31 155
- A61K31 522
- A61K31 7034
- A61K31 7048
- A61K45 06
- A61P39 00
- A61P39 06
- A61P43 00